Treatment Options for Multicentric Castleman's Disease

July 15, 2014
Frits van Rhee, MD, PhD, MRCP

Frits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.

Siltuximab is now approved for multicentric Castleman’s disease > >

Clinical Pearls

Frits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.

  • Multicentric Castleman's disease is a benign lymph node disorder in which patients get sick and notice lumps and bumps.
  • There is currently no standard of care for this group of patients who are not infected with HIV.
  • Being a rare disease, there have been no large studies conducted in this space.
  • Steroids and rituximab are commonly used to treat this disease.